Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of “Hold” by Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average recommendation of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $9.00.

INO has been the subject of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating and set a $6.00 price target (up previously from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. Zacks Research downgraded shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research note on Monday. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Tuesday. Finally, Citigroup restated a “market outperform” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, November 4th.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock opened at $1.76 on Wednesday. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $2.98. The stock has a market cap of $117.44 million, a P/E ratio of -0.68 and a beta of 1.54. The firm’s fifty day moving average price is $2.13 and its 200-day moving average price is $2.06.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.07. Sell-side analysts predict that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nuveen LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 1st quarter worth approximately $168,000. Charles Schwab Investment Management Inc. boosted its holdings in Inovio Pharmaceuticals by 38.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 98,495 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 27,429 shares in the last quarter. Nomura Holdings Inc. bought a new stake in Inovio Pharmaceuticals in the first quarter worth $28,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter worth $86,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 5,894 shares in the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.